NEW YORK, NY
Flatiron Health today announced 13 abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2019, which will be held September 27 – October 1, 2019, in Barcelona, Spain. The research, spanning multiple tumor types and areas of study, utilized Flatiron’s high-quality, real-world oncology datasets. Collectively, these research presentations highlight the various applications of real-world evidence, enabling deep clinical insights to better understand the use of biomarkers, comparative effectiveness of therapies and outcomes in routine clinical care.
Presentations include collaborator research by the U.S. Food & Drug Administration’s Oncology Center of Excellence, Huntsman Cancer Institute, Yale Cancer Center, Bayer, Bristol-Myers Squibb, Celgene, Merck, Pfizer, Roche/Genentech and Foundation Medicine.
The presentation schedule and links to abstracts can be found below.
Poster Discussion
First Author: Daniel Backenroth (Flatiron Health)
Date/Time: September 29 — 08:45 – 09:45
Presentation: #1877PD
Poster Sessions
First Author: Denis Talbot (University of Oxford)
Date/Time: September 28 — 12:00 – 13:00
Presentation: #1497P
First Author: David D. Stenehjem (University of Minnesota)
Date/Time: September 28 — 12:00 – 13:00
Presentation: #1498P
First Author: Matthew G. Krebs (The Christie NHS Foundation Trust)
Date/Time: September 28 — 12:00 – 13:00
Presentation: #1546P
First Author: Matthew G. Krebs (The Christie NHS Foundation Trust)
Date/Time: September 28 — 12:00 – 13:00
Presentation: #1551P
First Author: Aaron B. Cohen (Flatiron Health)
Date/Time: September 28 — 12:00 – 13:00
Presentation: #1558P
First Author: Xinran Ma (Flatiron Health)
Date/Time: September 28 — 12:00 – 13:00
Presentation: #1581P
First Author: Mylin Torres (Winship Cancer Institute, Emory University School of Medicine)
Date/Time: September 28 — 12:00 – 13:00
Presentation: #327P
First Author: Rachel M. Layman (Pfizer)
Date/Time: September 30 — 12:00 – 13:00
Presentation: #329P
First Author: Thibaut Sanglier (Roche)
Date/Time: September 30 — 12:00 – 13:00
Presentation: #356P
Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients
First Author: Xiaolong Jiao (Bayer)
Date/Time: September 30 — 12:00 – 13:00
Presentation: #102P
First Author: Aracelis Z. Torres (Flatiron Health)
Date/Time: September 30 — 12:00 – 13:00
Presentation: #1290P
Comparative-effectiveness of pembrolizumab vs nivolumab for patients with metastatic melanoma
First Author: Justin Moser (Huntsman Cancer Institute)
Date/Time: September 30 — 12:00 – 13:00
Presentation: #1346P
About Flatiron Health
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.